- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07801989
Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health (AK ACE-PATH)
30 de agosto de 2026 atualizado por: University of Alaska Fairbanks
Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska
The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Descrição detalhada
In Phase I of AK ACE, community partners identified and prioritized local stressors through a consensus-based process.
Building on these findings, Phase II will implement interventions targeting the highest-priority stressors through modules designed to improve health outcomes.This study addresses a critical gap in understanding local health and mental health among AN populations facing rapid social change and overlapping public health challenges.
The project focuses on developing community-driven solutions to improve physiological and mental health, particularly among youth, and to prevent chronic disease across the lifespan in rural Alaska.
To achieve these goals, the study will develop and implement Tools for Arctic Health Promotion (TAHP), a novel intervention integrating data-driven tools and evidence-based community strategies.
TAHP will support structured community engagement and deliver manualized health activities to approximately 410 adults and youth across five rural AN communities.
The TAHP intervention will be evaluated through a feasibility pilot in one community and a paired dynamic waitlisted design (DWLD) across four additional communities.
Behavioral and biological measures will assess individual- and community-level impacts on chronic disease prevention and mental health promotion.
Tipo de estudo
Intervencional
Inscrição (Estimado)
360
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Stacy Rasmus, PhD
- Número de telefone: 907-328-8919
- E-mail: smrasmus@alaska.edu
Estude backup de contato
- Nome: Hannah Robinson, MPH
- Número de telefone: 731-400-3539
- E-mail: hrobinson3@alaska.edu
Locais de estudo
-
-
Alaska
-
Fairbanks, Alaska, Estados Unidos, 99775
- University of Alaska Fairbanks
-
Contato:
- Maria Stejskal
- Número de telefone: 907-474-6230
- E-mail: mtrussell@alaska.edu
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- Self-identify as a permanent resident of the study community
- Be a youth between the ages of 12-17 years or an adult 18+
- Be able to provide written informed consent
Exclusion Criteria:
- Does not have permanent residence in the community or has lived in the community less than 5 years
- Is unable to provide written informed consent
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Enrollment in TAHP
The study will enroll 360 participants from four unique community settings to receive the TAHP intervention.
The study design will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3).
|
The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023).
A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives.
We will analyze how individual stress indicators are mitigated over time by intervention participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction.
We will assess how the intervention mitigates life satisfaction with individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks.
We will assess how the intervention impacts depressive symptoms with individual participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if food security increases using the food security index from the PhenX Toolkit
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health.
We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities.
This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree."
We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery Scale
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions.
It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks.
We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness Scale
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment.
This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections.
We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life Scale
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people.
It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide.
We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale
Prazo: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth.
This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement.
We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.
Prazo: Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response.
These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time.
Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day.
Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.
|
Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
21 de setembro de 2026
Conclusão Primária (Estimado)
31 de outubro de 2028
Conclusão do estudo (Estimado)
30 de abril de 2029
Datas de inscrição no estudo
Enviado pela primeira vez
25 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
30 de agosto de 2026
Primeira postagem (Real)
3 de setembro de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
3 de setembro de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
30 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 6922-06-CH-S001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .